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We undertook a two-stage genome-wide association study of Alzheimer's disease involving over
16,000 individuals. In stage 1 (3,941 cases and 7,848 controls), we replicated the established
association with the APOE locus (most significant SNP: rs2075650, p= 1.8×10−157) and observed
genome-wide significant association with SNPs at two novel loci: rs11136000 in the CLU or
APOJ gene (p= 1.4×10−9) and rs3851179, a SNP 5′ to the PICALM gene (p= 1.9×10−8). Both
novel associations were supported in stage 2 (2,023 cases and 2,340 controls), producing
compelling evidence for association with AD in the combined dataset (rs11136000: p= 8.5×10−10,
odds ratio= 0.86; rs3851179: p= 1.3×10−9, odds ratio= 0.86). We also observed more variants
associated at p< 1×10−5 than expected by chance (p=7.5×10−6), including polymorphisms at the
BIN1, DAB1 and CR1 loci.
Alzheimer's disease (AD) is the most common form of dementia, is highly heritable
(heritability of up to 76%) but genetically complex1. Neuropathologically, the disease is
characterized by extracellular senile plaques containing β-amyloid (Aβ) and intracellular
neurofibrillary tangles containing hyperphosphorylated τ protein1. Four genes have been
definitively implicated in its etiology. Mutations of the amyloid precursor protein (APP)
gene and the presenilin 1 and 2 genes (PSEN1, PSEN2) cause rare, Mendelian forms of the
disease usually with an early-onset. However, in the more common form of AD, only
apolipoprotein E (APOE) has been established unequivocally as a susceptibility gene1.
Aiming to identify novel AD loci, several genome-wide association studies (GWAS) have
been conducted prior to the present study. All have identified strong evidence for association
to APOE, but less convincing evidence implicating other genes2-9. This outcome is
consistent with the majority of findings from GWAS of other common phenotypes, where
susceptibility alleles typically have effect sizes with odds ratios (OR) of 1.5 or less, rather
than of the magnitude for APOE (OR~3). Detecting such modest effects requires much
larger samples than those that have been applied in the GWAS of AD to date10, which have
all included fewer than 1,100 cases. Based upon the hypothesis that risk alleles for AD are
likely to confer ORs in the range seen in other common diseases, we undertook a more
powerful GWAS than has been undertaken to date.
We established a collaborative consortium from Europe and the USA from which we were
able to draw upon a combined sample of up to 19,000 subjects (before quality control) and
conducted a two-stage study. In Stage 1, 14,639 subjects were genotyped on Illumina
platforms. 5,715 samples were genotyped for the present study using the Illumina 610-
quadchip; genotypes for the remaining subjects were either made available to us from
population control datasets or through collaboration and were genotyped on the Illumina
HumanHap550 or the HumanHap300 BeadChips. Prior to association analysis, all samples
and genotypes underwent stringent quality control, which resulted in the elimination of
53,383 autosomal SNPs and 2,850 subjects. Thus, in Stage 1, we tested 529,205 autosomal
SNPs for association in up to 11,789 subjects (3,941 AD cases, 7,848 controls of which
2,078 were elderly screened controls, see Supplementary Table 1). The genomic control
inflation factor (λ)11 was 1.037, suggesting little evidence for residual stratification.
In addition to the known association with the APOE locus, GWA analysis identified two
novel loci at a genome-wide level of significance (see Fig. 1). Table 1 shows SNPs which
were genome-wide significant (GWS) in stage 1; 13 GWS SNPS map within or close to the
APOE locus on chromosome 19 (p< 3×10−8 − 2×10−157) and the top 5 are shown in Table 1
(see Supplementary Table 2 for the complete list). The other two SNPs represent novel
associations. One of the novel SNPs (rs11136000) is located within an intron of clusterin
(CLU, also known as APOJ) on chromosome 8 (p= 1.4×10−9, OR=0.840); the other SNP
(rs3851179) is 88.5 kb 5′ to PICALM on chromosome 11 (p = 1.9×10−8, OR=0.849). Note
that there was no significant difference in allele frequencies between elderly, screened
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controls and population controls for these two SNPs. In stage 2, the two novel GWS SNPs
were genotyped in an independent sample comprising 2,023 AD cases and 2,340 age-
matched, cognitively screened controls (Supplementary Table 3). Both were independently
associated in this sample (rs11136000: one-tailed p= 0.017, OR= 0.905; rs3851179: one-
tailed p= 0.014, OR= 0.897). Meta-analysis of the stage 1 and 2 datasets also produced
highly significant evidence of association (rs11136000: p= 8.5×10−10, OR = 0.861 and
rs3851179: p= 1.3×10−9, OR= 0.859, two-tailed, Table 1) for CLU and PICALM loci
respectively. We sought further evidence from the Translational Genomics Research
Institute (TGEN) study9 and the Li et al. study8, two publicly available AD GWAS datasets,
but neither of the novel GWS SNPs had been genotyped or could be imputed. As secondary
analyses, we tested each novel finding for interaction with APOE status and for association
with age at onset. No significant interactions of the novel SNPs with APOE status were
observed influencing AD risk (rs11136000xAPOE-ε4 interaction p= 0.674;
rs3851179xAPOE-ε4 interaction p=0.735). Although we observed significant effects of the
GWS SNPs on age at onset, these were limited to SNPs at the APOE locus (data not shown).
In a preliminary attempt to attribute the source of the association to a functional variant, we
used publicly available data to identify additional SNPs at each locus that were correlated
through linkage disequilibrium (LD) with either novel GWS SNP or that might plausibly
have functional effects (see Supplementary Table 4). A synonymous SNP (rs7982) in the
CLU gene was in strong LD (r2=0.95 in our extension sample) with the GWS SNP and
showed a similar level of evidence for association with AD in the whole sample (meta-p
=8×10−10; stage 1 genotypes were imputed). This SNP is in exon 5 of the CLU gene, which
codes for part of the beta chain of the protein and may influence a predicted exon splicing
enhancer. We note that Tycko and colleagues12 previously published a negative association
study on the CLU gene, analyzing 4 SNPs in an AD case-control sample of African-
American, Hispanic and Caucasian/non-Hispanic individuals. Although they identified
rs7982 through mutation screening (referred to as VB in their study), the SNP was not tested
for association in their sample. The 4 SNPs that were analyzed were rare in Caucasians
(minor allele frequency <2%) and there was very limited power to detect association in their
Caucasian sub-sample of 53 AD cases and 43 controls. As these 4 SNPs were not genotyped
in the present GWAS, there is no overlap between the two studies.
Several potentially functional SNPs were identified at the PICALM locus. Of these, two
showed good evidence for association; rs561655, which is within a putative transcription
factor binding site and rs592297, which is a synonymous SNP in exon 5 of the gene that
may influence a predicted exon splicing enhancer. However, neither of these SNPs showed
the strength of evidence for association observed for rs3851179, the GWS SNP at the
PICALM locus (i.e. rs561655: meta-p= 1×10−7 and rs592297: meta-p= 2×10−7). A number
of SNPs in LD with rs3851179 and showing moderate evidence of association in the GWAS
(p<1×10−4) were also followed up, most notably rs541458. This SNP is 8kb 5′ to the
PICALM gene and was directly genotyped in the extension sample, the TGEN study and the
Li et al. study, with p<0.05 in each. Following meta-analysis, this is one of our most
significant SNPs (meta-p= 8×10−10) and is also supported by the study of Amouyel et al.
published in this issue (p=3×10−3). Further genetic analyses will be required to characterize
the true nature of the associations observed at these loci, which is beyond the scope of this
paper.
We also tested whether the observed number of significant associations observed in the
GWAS exceeded what would be expected by chance. Having removed SNPs within the
APOE, CLU and PICALM loci (see Methods) we focused on those which showed most
evidence for association (p< 1×10−5). Approximately 13 independent signals were observed;
less than 4 would be expected by chance (p= 7.5×10−6). Table 2 shows the loci implicated
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and provides strong evidence for association with the complement receptor 1 (CR1) gene,
particularly in the context of the results of the Amouyel et al. study published in this issue.
Also noteworthy are the bridging integrator 1 (BIN1) gene, which produces a protein
involved in synaptic vesicle endoctyosis13, and the disabled homolog 1 (DAB1) gene,
whose product is involved with tyrosine phosphorylation and microtubule function in
neurons14. These data thus provide strong evidence that there are several genes associated
with AD which remain to be identified. We have also tested over 100 variants highlighted
by previous AD GWA studies for association in our sample (see Supplementary note for full
discussion). These are summarized in Supplementary Table 5.
Until now, the APOE-ε4 allele was the only consistently replicated genetic risk factor for
AD. It is therefore intriguing that we find compelling evidence for association with CLU, a
gene that encodes another major brain apolipoprotein15, suggesting that susceptibility genes
are not randomly distributed through functional pathways. The predominant form of
clusterin is a secreted heterodimeric glycoprotein of 75-80kDa. The single copy gene spans
about 16kb on chromosome 8p21-p12 and encodes an mRNA of approximately 2kb that
translates into a 449 amino acid primary polypeptide chain. Clusterin is expressed in all
mammalian tissues16 and there is strong evidence that CLU levels are elevated in a number
of pathological conditions involving injury or chronic inflammation of the brain17. In
Alzheimer's disease brain, CLU expression is reported to be increased in affected cortical
areas and is present in amyloid plaques and in the cerebrospinal fluid of AD cases17-20.
Clusterin is a multi-functional molecule. It interacts with the soluble form of Aβ in animal
models of disease and binds soluble Aβ in a specific and reversible manner, forming
complexes that have been shown to cross the blood-brain barrier21-24. Interestingly, APOE
also appears to act as a molecular chaperone for Aβ and influences when it aggregates and
deposits25 as well as influencing Aβ conformation and toxicity26,27. In a similar way,
clusterin appears to regulate both the toxicity and conversion of Aβ into insoluble
forms28-32. Furthermore, APOE and CLU have been shown to cooperate in suppressing Aβ
deposition33 and APOE and CLU may critically modify Aβ clearance at the blood brain
barrier, suggesting a role for clusterin in the amyloidogenic pathway34. Levels of APOE
protein appear to be inversely proportional to APOE-ε4 allele dose levels, i.e. expression
levels are reduced in ε4 homozygotes compared with heterozygotes. Conversely, CLU
levels are increased in proportion to APOE-ε4 allele dose suggesting an induction of
clusterin in individuals with low APOE levels35. Thus, the strong statistical evidence for the
involvement of this gene in AD has additional support in terms of biological plausibility.
The second gene locus to show compelling evidence for association with AD is PICALM
(phosphatidylinositol-binding clathrin assembly protein; also known as CALM: clathrin
assembly lymphoid-myeloid leukemia gene). PICALM is ubiquitously expressed in all
tissue types with prominent expression in neurons, where it is nonselectively distributed at
the pre- and post synaptic structures. It has been shown that like BIN1, PICALM is involved
in clathrin-mediated endocytosis (CME), an essential step in the intracellular trafficking of
proteins and lipids such as nutrients, growth factors and neurotransmitters36-38. Of
relevance to AD, PICALM appears to be involved in directing the trafficking of VAMP2.
VAMP2 is a SNARE protein that plays a prominent role in the fusion of synaptic vesicles to
the presynaptic membrane in neurotransmitter release, a process that is crucial to neuronal
function39. AD brains show a reduced number of synapses and stereological and
biochemical analysis has shown that this reduction in synaptic density correlates with
cognitive defects better than the accumulation of plaques and tangles40. More recent
analysis indicates synapses within AD brains may be dysfunctional even before they visibly
degenerate41. Therefore, we can hypothesize that genetically directed changes in PICALM
function result in perturbations at the synapse, possibly through synaptic vesicle cycling,
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thereby increasing risk for AD. Alternatively, PICALM could influence risk of AD through
APP processing via endocytic pathways resulting in changes in Aβ levels. Cell culture
experiments have shown that full length APP is retrieved from the cell surface by CME42
and inhibition of endocytosis reduces APP internalization and reduces Aβ production and
release43,44. Increased synaptic activity is known to lead to the elevated endocytosis of
synaptic vesicle proteins and Cirrito et al. have since provided evidence in vivo that the
increased CME, triggered by increased synaptic activity, drives more APP into endocytotic
compartments resulting in an increase of Aβ production and release45. Thus, as for
clusterin, the strong statistical evidence for the involvement of PICALM in AD has support
in terms of biological plausibility.
The power of the present study to detect loci of the effect sizes observed in the GWAS for
rs11136000 and rs3851179 at a genome-wide significance level is 0.74 and 0.57,
respectively. However, it is widely acknowledged that effect sizes of significant loci
obtained from genome-wide studies are over-estimates of the true effects46. In the extension
study, rs11136000 had an OR of 0.905, while rs3851179 had an OR of 0.897. Assuming that
these better reflect the true effect sizes associated with these loci, the GWAS has power to
detect genome-wide significant association of 0.026 and 0.041 respectively. Thus it is likely
that there are other genes of similar effect sizes that did not reach genome-wide significance.
Indeed, we observed many SNPs which, while failing to reach this stringent level of
statistical significance, might still reflect true associations with disease, e.g. variants at the
CR1 locus, also highlighted by the results of Amouyel and colleagues (this issue). As with
other GWAS research into complex disorders, such as Type 2 diabetes where 18
susceptibility loci have now been confirmed through GWAS meta-analysis of 54,000
subjects47, further larger GWAS are required to identify new susceptibility variants for AD.
Methods
Sample ascertainment and diagnostic criteria
The study comprised a Stage 1 discovery sample of 4,957 AD cases and 9,682 controls and
a Stage 2 follow-up sample of 2,023 AD cases and 2,340 controls. See the Supplementary
note for a complete description of the study subjects.
Stage 1 Genotyping
Genotyping was performed at the Sanger Institute, UK. 200ng of input DNA per sample
were used and prepared for genotyping using the Illumina Infinium™ system (Illumina®
Inc., San Diego, CA, USA). Manufacturer's protocols were followed throughout. The
Illuminus algorithm for cluster analysis was used for genotype calling49.
Stage 1: Individual Quality Control
4,113 AD cases and 1,602 controls were genotyped on the Illumina 610-quad chip as part of
this study (the 610 group). In addition, 844 AD cases and 8,080 controls previously
genotyped using either the Illumina HumanHap550 or Illumina HumanHap300 were
included in the analysis. These genotypes were generated as part of 7 different studies,
making 8 separate groups in total: 1) 610; 2) Mayo; 3) 1958 birth cohort (Sanger); 4) 1958
birth cohort (T1DGC); 5) ALS control; 6) Coriell control; 7) Heinz Nixdorf Recall (HNR)
study; 8) KORA F4. As we used genotype data from multiple sources, it was important to
apply stringent QC filters, as differential genotyping error rates between groups could result
in spurious associations when the data are combined50,51. These filters were applied
separately to each of these 8 groups to remove poorly performing samples using tools
implemented in PLINK v1.0552.
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We removed 1,469 individuals with missing genotype rates > 0.01. We also applied a filter
based on mean autosomal heterozygosity, excluding 578 individuals with values above or
below empirically determined thresholds. 71 individuals with inconsistencies between
reported gender and genotype-determined gender and 22 individuals with ambiguous
genotype-determined gender were removed. All individuals passing these QC filters were
examined for potential genetic relatedness by calculating identity by descent (IBD) estimates
for all possible pairs of individuals in PLINK, and removing one of each pair with an IBD
estimate ≥ 0.125 (the level expected for first cousins). IBD estimates were calculated using
SNPs that were common to the Illumina 610, 550 and 300 chips with a genotype missing
data rate ≤ 0.01, Hardy-Weinberg P ≥ 1×10−5 and a minor allele frequency ≥ 0.01. As a
result, 506 individuals were excluded (note that this includes 311 individuals that were
included in both the Coriell and ALS control group).
We also sought to detect non-European ancestry. To this end, genotype data from SNPs
typed in all cohorts was merged with genotypes at the same SNPs from 210 unrelated
European (CEU), Asian (CHB and JPT) and Yoruban (YRI) samples from the HapMap
project. Subsequent to removing SNPs in extensive regions of linkage disequilibrium
(chr5:44-51.5 Mb; chr6: 25-33.5 Mb; chr8: 8-12 Mb; chr11: 45-57 Mb)53, we further
pruned SNPs if any pair within a 50-SNP window had r2 > 0.2. Genome-wide average
identity by state (IBS) distance was calculated in PLINK between each pair of individuals in
the resulting dataset, based on 57,966 SNPs (all with a genotype missing data rate ≤ 0.01,
Hardy-Weinberg P ≥ 1×10−5 and a minor allele frequency ≥ 0.01). The resulting matrix of
IBS distances was used as input for classical multi-dimensional scaling (MDS) in R v2.7.1.
When the first two dimensions were extracted and plotted against each other, three clusters
were observed corresponding to the European, Asian and Yoruban samples. Sixteen samples
appeared to be ethnic outliers from the European cluster and were excluded from further
analysis.
We assessed population structure within the data using principal components analysis (PCA)
as implemented in EIGENSTRAT54 to infer continuous axes of genetic variation.
Eigenvectors were calculated based on the previously described LD-pruned subset of 57,966
SNPs common to all arrays. The EIGENSTRAT program also identifies genetic outliers,
which are defined as individuals whose ancestry is at least 6 standard deviations from the
mean on one of the top ten axes of variation. As a result, 188 outliers were identified and
excluded. Following sample QC 3,941 AD cases and 7,848 controls were included in the
analysis.
Stage 1: SNP Quality Control
Due to unresolved genotype-calling issues with a proportion of SNPs on the sex
chromosomes, only autosomal SNPs were included in this analysis (with the exception of
rs5984894, an X chromosome SNP that has previously been associated with AD by
Carrasquillo et al.5; see Supplementary Table 5). Individuals were genotyped on either the
Illumina 610-quad as part of this project, or were previously genotyped on the Illumina
HumanHap550 or the Illumina HumanHap300 array, and the genotypes made available to
us. Note that SNPs had already been filtered out of some groups prior to inclusion in this
study. Moreover, where different versions of the same array were used (e.g.
HumanHap550v1 used to genotype the 1958 birth cohort (Sanger) cohort compared with the
HumanHap550v3 array used to genotype the 1958 birth cohort (T1DGC)), only SNPs
common to both versions were considered as present on that array. As such, SNPs included
in our analysis fell into 4 different categories; 1) 266,714 SNPs common to all 3 arrays and
genotyped in all individuals; 2) 202,516 SNPs common to the 610 and 550 arrays, but not
present or without genotypes in individuals typed on the 300 array; 3) 7,744 SNPs common
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to the 610 and 300 arrays, but not present or without genotypes in individuals typed on the
550 array; 4) 105,614 SNPs with genotypes only in the 610 data.
We assessed the effects of different missing data rate and Hardy-Weinberg filters, aiming to
remove poorly performing SNPs without excluding markers that may show genuine
association with AD. For each of the 4 SNP categories, markers were excluded if they had a
minor allele frequency (MAF) < 0.01 or a Hardy-Weinberg P ≤ 1×10−5, in either cases or
controls. SNPs with a MAF ≥ 0.05 were excluded if they had a genotype missing rate of >
0.03 in either cases or controls; for SNPs with a MAF between 0.01 and 0.05, a more
stringent genotype missing rate threshold of 0.01 was employed. As a result of this basic
SNP QC 43,542 SNPs were excluded.
Ten principal components (PCs) were extracted using EIGENSTRAT, as previously
described. To determine if the PCs could assuage any population structure within our
sample, we performed logistic regression tests of association with AD, sequentially
including between 0 and 10 of the top PCs as covariates. The impact of including the PCs
was evaluated by calculating the genomic control inflation factor, λ11. We found that
including the first 4 PCs as covariates had the maximum impact on λ.
To minimize inter-chip and inter-cohort differences that could result in an inflation of type I
error rate, minor allele frequencies were compared between controls in the different groups
using logistic regression analysis, incorporating the top 4 PCs as covariates as previously
described. Comparisons were only performed between individuals from the same
geographical region (i.e. British Isles, Germany or USA). For each of the 4 categories of
SNPs, a quantile-quantile (Q-Q) plot was produced for each cohort control comparison, and
the significance threshold employed to exclude SNPs was based on where the observed χ2
statistics departed from the null expectation. A further 9,828 SNPs were excluded as a result
of these comparisons. Thus, a total of 529,218 autosomal SNPs were analyzed for
association with AD in this study.
Stage 1 Statistical Analysis
SNPs were tested for association with AD using logistic regression, assuming an additive
model. Covariates were included in the logistic regression analysis to allow for geographical
region and chip, i.e. to distinguish between 1) individuals from the British Isles, 2)
individuals from Germany, 3) individuals from the US typed on the 610 or 550 chip, 4)
individuals from the US typed on the 300 chip. It was not possible to include a covariate for
each chip as only controls were genotyped on the 550 chip. Similarly, it was not possible to
include a covariate for each of the 8 groups, as only two included both cases and controls
(610 and Mayo groups). The first 4 PCs extracted from EIGENSTRAT were also included
as covariates, as previously described. Following analysis, 130 cluster plots were visually
inspected for SNPs with a p-value ≤ 1×10−4. Thirteen SNPs showing poorly formed clusters
were excluded. Thus our analysis was based on 529,205 SNPs, and a conservative genome-
wide significance threshold of 0.05/529205 = 9.4×10−8 was employed. The overall genomic
control inflation factor, λ, was calculated to be 1.037. Population attributable risk (the
expected reduction in disease load following removal of a risk factor) was calculated for
GWS SNPs according to the formula: PAR = Fcon(OR-1)/[Fcon(OR-1)+1], where Fcon is the
frequency of the risk allele in controls and OR is the odds ratio associated with the risk
allele55.
Expected number of significant SNPs
We assessed our results to determine if we observed more significant SNPs than would be
expected by chance. We first removed SNPs within 500 kb either side of risk SNPs, i.e.
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rs429358 (the APOE ε4 SNP), rs11136000 (CLU) and rs3851179 (PICALM). We thus
excluded 170 “APOE” SNPs, 290 “CLU” SNPs and 257 “PICALM” SNPs. Of the 528,448
remaining SNPs we estimated 397,224.7 “independent” tests using the algorithm we
described in 56. Of 16 SNPs significant at a significance level α=10−5 (excluding APOE,
CLU and PICALM SNPs, see Table 2) we estimated 12.6 “independent” tests. We
calculated the mean (N*α =397224.7*10−5 ≈ 4.0) and variance (N*α*(1-α) = 3.97) of the
expected number of significant tests at α=10−5 level using the binomial distribution. Thus
the probability of observing 12.6 significant tests is P = 7.5×10−6.
Stage 2 Genotyping and Statistical Analysis
We genotyped SNPs in cases and controls from 5 European cohorts (described in
Supplementary Table 3). Putative functional SNPs were identified using PupaSuite57.
Genotyping was performed at Cardiff using the MassARRAY and iPlexGOLD systems
(Sequenom, San Diego, CA) according to manufacturer's recommendations. All genotyped
SNPs had genotype call frequency rates >90% in the follow-up sample, and no SNPs had
HWE P-value ≤ 0.05 in cases or controls. SNPs were tested for association with AD using
logistic regression, assuming an additive model. Covariates were included in the logistic
regression analysis to allow for each cohort, i.e. 1) Belgium, 2) MRC, 3) ART, 4) Bonn, 5)
Greek.
Meta-analysis
We included genotype data from stages 1 and 2 in a meta-analysis for SNPs at the CLU and
PICALM loci. In addition, we employed genotype data from the TGEN study and the Li et
al. study, two publicly available AD GWAS datasets. The TGEN sample is comprised of
861 AD cases and 550 controls genotyped on the Affymetrix 500K chip. The Li et al.
discovery sample is comprised of 753 AD cases and 736 controls also genotyped on the
Affymetrix 500K chip. If a SNP of interest was not genotyped in our GWAS or the TGEN
dataset, an attempt was made to impute genotypes in PLINK, using the 60 HapMap CEU
founders as a reference panel. Only imputed SNPs with an information content metric value
greater than 0.8 were included in analysis (see PLINK website). Individual level data were
not available for the Li study and so SNPs could not be imputed. Where individual level data
was available, SNPs were tested for association with AD using logistic regression, assuming
an additive model. Covariates were included in the logistic regression analysis to allow for
geographical region and chip as in Stage 1 and for cohort as in Stage 2. Covariates included
for the TGEN sample distinguished between samples from the Netherlands Brain Bank and
samples from the USA. Meta-analyses incorporating data from the Li et al. study are based
on Mantel-Haenzsel χ2 tests. Results of the meta-analysis are shown in Table 1 and
Supplementary Table 4.
Secondary Analyses
We also tested the GWS SNPs for relationships with age at onset (AAO). To this end, age at
onset (in years) was employed as the dependent variable in a linear regression analysis and
an additive model was assumed. AAO data was available for 2,856 AD cases. Covariates
were included in the logistic regression analysis to allow for geographical region and chip,
i.e. to distinguish between 1) cases from the British Isles, 2) cases from Germany, 3) cases
from the US typed on the 610 chip, 4) cases from the US typed on the 300 chip.
In addition, we stratified our sample based on presence/absence of at least 1 APOE ε4 allele.
We had APOE genotype data for 6045 individuals; our ε4-positive sample consisted of
2,203 AD cases and 632 controls; our ε4-negative sample consisted of 1,446 cases and
1,764 controls. We performed genome-wide tests for association with AD in each sub-
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sample, but no SNP achieved genome-wide significance (see Supplementary Tables 6 and
7).
URLs
VIB Genetic Service Facility, http://www.vibgeneticservicefacility.be
TGEN, http://www.tgen.org
Haploview, http://www.broad.mit.edu/mpg/haploview
PLINK, http://pngu.mgh.harvard.edu/~purcell/plink
R, http://www.r-project.org
The GWAS data will be made available to bona fide researchers within 6 months (contact
the corresponding authors for access).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Scatterplot of chromosomal position (x-axis) against −log 10 GWAS P-value (y-axis). The y-
axis scale has been limited to 9.25 (p = 5.6×10−10), although highly significant association
was observed with SNPs in the vicinity of the APOE locus (e.g. rs2075650 with p =
1.8×10−157). The threshold for genome-wide significance (p ≤ 9.4×10−8) is indicated by the
red horizontal line. 761 SNPs with p ≤ 1×10−3 lie above the blue horizontal line and are
listed in Supplementary Table 2. The plot was produced using Haploview v4.048.
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